$60.34
+1.4%The Cooper Companies, Inc., together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment offers spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, myopia, ocular dryness and eye fatigues in the Americas, Europe, Middle East, Africa, and Asia Pacific. The CooperSurgical segment focuses on family and women's health care, which provides medical devices, fertility, genomics, diagnostics, and contraception to health care professionals and patients worldwide. It offers surgical and office products, including PARAGARD, uterine manipulators, retractors, closure products, point of care products, LEEP products, endosee, and illuminate and fetal pillows; fertility products and services, such as fertility consumables and equipment, and embryo options and preimplantation genetic testing. The Cooper Companies, Inc. was founded in 1958 and is headquartered in San Ramon, California.
Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.
Healthy operating margins demonstrate effective cost control and strong business fundamentals.
Moderate profitability with room for improvement. Monitor interest expenses and tax efficiency.
Higher tax burden may reflect limited tax optimization or operations in high-tax jurisdictions.
High margin compression: Large gap between gross and net margins suggests operational inefficiencies or heavy debt burden. Focus on expense management and deleveraging.
COO โข NASDAQ
| The Cooper Companies, Inc. Income Statement | Oct 2025 | Oct 2024 | Oct 2023 | Oct 2022 | Oct 2021 | Oct 2020 | Oct 2019 | Oct 2018 | Oct 2017 | Oct 2016 | Oct 2015 | Oct 2014 | Oct 2013 | Oct 2012 | Oct 2011 | Oct 2010 | Oct 2009 | Oct 2008 | Oct 2007 | Oct 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
REVENUE | ||||||||||||||||||||
4.1B | 3.9B | 3.6B | 3.3B | 2.9B | 2.4B | 2.7B | 2.5B | 2.1B | 2B | 1.8B | 1.7B | 1.6B | 1.4B | 1.3B | 1.2B | 1.1B | 1.1B | 950.6M | 859M | |
GROSS PROFIT | ||||||||||||||||||||
(1.6B) | (1.3B) | (1.2B) | (1.2B) | (966.7M) | (896.1M) | (896.6M) | (900.5M) | (773.2M) | (793.7M) | (726.8M) | (626.2M) | (560.9M) | (521.1M) | (526M) | (481.8M) | (483.9M) | (437.3M) | (431.1M) | (333M) | |
2.5B | 2.6B | 2.4B | 2.1B | 2B | 1.5B | 1.8B | 1.6B | 1.4B | 1.2B | 1.1B | 1.1B | 1B | 924M | 804.8M | 676.7M | 596.5M | 610M | 519.5M | 526M | |
OPERATING INCOME | ||||||||||||||||||||
(1.8B) | (1.9B) | (1.8B) | (1.6B) | (1.5B) | (1.2B) | (1.2B) | (1.2B) | (936.7M) | (849M) | (833.6M) | (785.1M) | (685.7M) | (635.6M) | (577.2M) | (486.4M) | (442.8M) | (481.5M) | (464M) | (406.7M) | |
(1.6B) | (1.5B) | (1.5B) | (1.3B) | (1.2B) | (992.5M) | (996.6M) | (973.3M) | (799.1M) | (722.8M) | (712.5M) | (683.1M) | (596.7M) | (559.9M) | (513.1M) | (433.1M) | (391.6M) | (429.3M) | (408M) | (357.8M) | |
(172.2M) | (155.1M) | (137.4M) | (110.3M) | (92.7M) | (93.3M) | (86.7M) | (84.8M) | (69.2M) | (65.4M) | (69.6M) | (66.3M) | (58.8M) | (51.7M) | (43.6M) | (35.3M) | (33.3M) | (35.5M) | (39.9M) | (34.5M) | |
682.9M | 705.7M | 533.1M | 507.6M | 505.8M | 311.8M | 546.7M | 403.1M | 429.1M | 324.1M | 236.7M | 306.5M | 305.9M | 283.4M | 227.6M | 189.9M | 149.9M | 127M | 45.9M | 112.9M | |
PRE-TAX INCOME | ||||||||||||||||||||
(100M) | (114.3M) | (105.3M) | (57.3M) | (23.1M) | (36.8M) | (68M) | (82.7M) | (33.4M) | (26.2M) | (18.1M) | (8M) | (9.2M) | (11.8M) | (17.3M) | (36.7M) | (44.1M) | (53.8M) | (67.5M) | (58.7M) | |
-100M | -114.3M | -105.3M | -57.3M | -23.1M | -36.8M | -68M | -82.7M | -33.4M | -26.2M | -18.1M | -8M | -9.2M | -11.8M | -17.3M | -36.7M | -44.1M | -50.8M | 0.0 | 0.0 | |
(0.0) | (201.2M) | (186.2M) | (179.5M) | (146.1M) | (137.2M) | (145.8M) | (146.7M) | (68.4M) | (60.8M) | (51.5M) | (35.7M) | (30.2M) | (24M) | (20.5M) | (18.1M) | (17.9M) | (16.8M) | (16.2M) | (14.3M) | |
-116.4M | -123.4M | -120.2M | -32.3M | -14.3M | -45.3M | -91.4M | -71.2M | -35.1M | -28.5M | -21.2M | -10M | 6.3M | -7.9M | -34.8M | -65.5M | -35M | -50.8M | -45.2M | -39.6M | |
566.5M | 582.3M | 412.9M | 475.3M | 491.5M | 266.5M | 477.4M | 331.9M | 394M | 295.6M | 215.5M | 296.5M | 312.3M | 275.5M | 192.8M | 124.4M | 114.8M | 76.2M | 672K | 73.3M | |
NET INCOME | ||||||||||||||||||||
(191.6M) | (190M) | (118.7M) | (89.5M) | -2.5B | (28.1M) | (10.7M) | (192M) | (21.1M) | (20.7M) | (10.3M) | (24.7M) | (15.4M) | (26.8M) | (17.3M) | (11.6M) | (14.3M) | (10.7M) | (11.9M) | (7.1M) | |
374.9M | 392.3M | 294.2M | 385.8M | 2.9B | 238.4M | 466.7M | 139.9M | 372.9M | 273.9M | 203.5M | 269.9M | 296.2M | 248.3M | 175.4M | 112.8M | 100.5M | 65.5M | -11.2M | 66.2M |
COO - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 04, 2026 | May 04, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 08, 2026 | April 07, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | March 06, 2026 | January 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 05, 2026 | March 05, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | February 24, 2026 | April 07, 2026 | 2026 | |
8-K 8-K 2026 N/A | February 04, 2026 | February 03, 2026 | 2026 | |
8-K 8-K 2025 N/A | December 23, 2025 | December 22, 2025 | 2025 | |
8-K 8-K 2025 N/A | December 12, 2025 | December 09, 2025 | 2025 | |
10-K 10-K 2025 FY FY | December 05, 2025 | October 31, 2025 | 2025 | |
8-K 8-K 2025 N/A | December 04, 2025 | December 04, 2025 | 2025 |
Continue your COO research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.